Quality of life in patients with metastatic colorectal cancer receiving maintenance therapy after first-line inductive treatment: A quality of life sub-analysis of the AIO KRK 0207 phase III trial

被引：1

作者：

Quidde, J. t ^{[1
]}

Becker, S. Hegewisch ^{[2
]}

Graeven, U. ^{[3
]}

Lerchenmueller, C.

Killing, B. ^{[4
]}

Depenbusch, R.

Steffens, C. -C.

Lange, T. ^{[5
]}

Dietrich, G. ^{[6
]}

Stoehlmacher, J. ^{[7
]}

Reinacher, A. ^{[8
]}

Tannapfel, A. ^{[9
]}

Trarbach, T. ^{[10
]}

Marschner, N.

Schmoll, H. J. ^{[11
]}

Hinke, A. ^{[12
]}

Al-Batran, S. -E. ^{[13
]}

Arnold, D. ^{[14
]}

机构：

[1] Univ Hamburg Hosp, Univ Canc Ctr Hamburg, Hamburg, Germany

[2] HOPE, Internal Med Oncol & Hematol, Hamburg, Germany

[3] Kliniken Maria Hilf GmbH, Klin Haematolgie Onkol, Monchengladbach, Germany

[4] Lahn Dill Kliniken, Dept Hematol & Oncol, Wetzlar, Germany

[5] Asklepios Klin Weissenfels, Dept Hematol & Oncol, Weissenfels, Germany

[6] Klinikum Bietigheim, Dept Gastroenterol Hematol & Oncol, Bietigheim, Germany

[7] Tumorgenetik, Bonn, Germany

[8] Ruhr Univ Bochum, Med Univ Klin, Med Dept, Bochum, Germany

[9] Ruhr Univ Bochum, Med Univ Klin, Dept Pathol, Bochum, Germany

[10] IOMEDICO AG, Med Dept, Freiburg, Germany

[11] Martin Luther Univ Halle Wittenberg, Dept Hematol Oncol FG U1 16, Halle, Germany

[12] WiSP GmbH, Res, Langenfeld, Germany

[13] Nordwest Krankenhaus, Med Oncol, Frankfurt, Germany

[14] CUF Hosp Canc Ctr, CUF, Lisbon, Portugal

来源：

ANNALS OF ONCOLOGY | 2016年 / 27卷

关键词：

D O I：

10.1093/annonc/mdw370.105

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

557P

引用

页数：1

共 50 条

[21] Quality of life in patients with lymphoproliferative neoplasms at diagnosis and after the first-line treatment
Szeja, Nicola Elibieta
Grosicki, Sebastian
ADVANCES IN CLINICAL AND EXPERIMENTAL MEDICINE, 2022, 31 (11): : 1207 - 1214
[22] Health-related quality of life in patients with RAS wild-type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: An analysis of the Panama trial (AIO KRK0212).
Ballhausen, Alexej
Karthaus, Meinolf
Fruehauf, Stefan
Graeven, Ullrich
Mueller, Lothar
Koenig, Alexander
von Weikersthal, Ludwig Fischer
Sommerhaeuser, Greta
Alig, Annabel Helga Sophie
Goekkurt, Eray
Haas, Siegfried
Kurreck, Annika
Stahler, Arndt
Held, Swantje
Reinacher-Schick, Anke C.
Kasper, Stefan
Heinemann, Volker
Stintzing, Sebastian
Trarbach, Tanja
Modest, Dominik Paul
JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 : 51 - 51
[23] A randomized phase II trial of capecitabine and two different schedules of irinotecan in first-line treatment of metastatic colorectal cancer: efficacy, quality-of-life and toxicity
Borner, MM
Bernhard, J
Dietrich, D
Popescu, R
Wernli, M
Saletti, P
Rauch, D
Herrmann, R
Koeberle, D
Honegger, H
Brauchli, P
Lanz, D
Roth, AD
ANNALS OF ONCOLOGY, 2005, 16 (02) : 282 - 288
[24] Impact of the Localization of the Primary Tumor and RAS/BRAF Mutational Status on Maintenance Strategies After First-line Oxaliplatin, Fluoropyrimidine, and Bevacizumab in Metastatic Colorectal Cancer: Results From the AIO 0207 Trial
Noepel-Duennebacke, Stefanie
Arnold, Dirk
Hertel, Jan
Tannapfel, Andrea
Hinke, Axel
Hegewisch-Becker, Susanna
Reinacher-Schick, Anke
CLINICAL COLORECTAL CANCER, 2018, 17 (04) : E733 - E739
[25] The impact of cumulative toxicity on physical quality of life in patients with metastatic colorectal cancer receiving first line chemotherapy.
Schuurhuizen, Claudia
Konings, Inge
Braamse, Annemarie
Buffart, Laurien
Bloemendal, Haiko
Dekker, Joost
Verheul, Henk M. W.
JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
[26] Erlotinib added to bevacizumab as maintenance therapy and health-related quality of life in patients with metastatic colorectal cancer: results of the GERCOR DREAM phase III trial
Anota, Amelie
Vernerey, Dewi
Tournigand, Christophe
Chibaudel, Benoist
Samson, Benoit
Scheithauer, Werner
Brusquant, David
Andre, Thierry
de Gramont, Aimery
Bonnetain, Franck
QUALITY OF LIFE RESEARCH, 2016, 25 : 112 - 112
[27] Gender-dependent survival benefit from first-line irinotecan in metastatic colorectal cancer. Subgroup analysis of a phase III trial (XELAVIRI-study, AIO-KRK-0110)
Heinrich, Kathrin
Modest, Dominik P.
Ricard, Ingrid
von Weikersthal, Ludwig Fischer
Decker, Thomas
Kaiser, Florian
Graeven, Ullrich
Uhlig, Jens
Schenk, Michael
Freiberg-Richter, Jens
Peuser, Bettina
Denzlinger, Claudio
Giessen-Jung, Clemens
Stahler, Arndt
Michl, Marlies
Held, Swantje
Jung, Andreas
Kirchner, Thomas
Stintzing, Sebastian
Heinemann, Volker
EUROPEAN JOURNAL OF CANCER, 2021, 147 : 128 - 139
[28] The predictive value of cumulative toxicity for quality of life in patients with metastatic colorectal cancer during first-line palliative chemotherapy
Schuurhuizen, Claudia S. E. W.
Verheul, Henk M. W.
Braamse, Annemarie M. J.
Buffart, Laurien M.
Bloemendal, Haiko J.
Dekker, Joost
Konings, Inge R. H. M.
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3015 - 3021
[29] Health-related quality of life in patients with RAS wild- type metastatic colorectal cancer treated with fluorouracil and folinic acid with or without panitumumab as maintenance therapy: a prespecified secondary analysis of the PanaMa (AIO KRK 0212) trial
Ballhausen, Alexej
Karthaus, Meinolf
Fruehauf, Stefan
Graeven, Ullrich
Mueller, Lothar
Koenig, Alexander Otto
von Weikersthal, Ludwig Fischer
Sommerhaeuser, Greta
Alig, Annabel Helga Sophie
Goekkurt, Eray
Meyer-Knees, Johanna Wanda
Kurreck, Annika
Stahler, Arndt
Held, Swantje
Kasper, Stefan
Heinrich, Kathrin
Heinemann, Volker
Stintzing, Sebastian
Trarbach, Tanja
Modest, Dominik Paul
EUROPEAN JOURNAL OF CANCER, 2023, 190
[30] QUALITY OF LIFE ANALYSIS IN PATIENTS WITH KRAS WILD-TYPE METASTATIC COLORECTAL CANCER TREATED WITH FIRST-LINE FOLFIRI PLUS CETUXIMAB
Lang, I.
Koehne, C.
Folprecht, G.
Rougier, P.
Curran, D.
Hitre, E.
Sartorius, U.
Griebsch, I.
Van Cutsem, E.
ANNALS OF ONCOLOGY, 2012, 23 : 191 - 192

← 1 2 3 4 5 →